Amgen Said to Boost Bid for Onyx to $130 a Share

Aug. 6 (Bloomberg) -- Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to a person familiar with the matter. Olivia Sterns reports on Bloomberg Television's "Street Smart." (Source: Bloomberg)

Here's Why Chinese Egg Futures Are at a Record
53:58 - Bloomberg's Anna Kitanaka reports on Chinese egg futures. She speaks on "Bloomberg Markets." (Source: Bloomberg)
  • Minsheng Bank Says Head Detained, Accounts Frozen
  • JPMorgan's Ulrich Sees Satisfactory China Bank Earnings
  • China's Middle Class Angst